Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
← catalyst calendarNCT07441408 · readout in 1,191 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2,380estimated
Sites
275
Countries
Argentina, Australia, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-12-16 | estimated | When the study began enrolling |
| Primary completion | 2029-11-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Fibrosis
Intervention
- Drug: BMS-986278 — also filed as Admilparant
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to Week 100
Number of Participants With Serious Adverse Events (SAEs)
measured Up to Week 100
Number of Participants With AEs leading to Discontinuation
measured Up to Week 100
Number of Participants With AEs leading to Deaths
measured Up to Week 100
Number of Participants With Clinically Significant Laboraty Abnormalities
measured Up to Week 100
Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities
measured Up to Week 100
Number of Participants With Clinically Significant Vital Sign Abnormalities
measured Up to Week 100
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed